You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

non-anthracycline trastuzumab

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

During Non-anthracycline Trastuzumab-based Therapy in Breast

Recruiting
  • Breast Cancer
  • Left Ventricular Ejection Fraction
  • Hartford, Connecticut
  • +7 more
Mar 7, 2022

Cardiomyopathy Trial in Baltimore (Metoprolol)

Terminated
Has Results
  • Cardiomyopathy
  • Baltimore, Maryland
    University of Maryland
Feb 23, 2022

Malignant Solid Tumor Trial in Philadelphia (Biopsy, Biospecimen Collection, Echocardiography)

Active, not recruiting
  • Malignant Solid Neoplasm
  • Biopsy
  • +5 more
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
Nov 15, 2023

Metastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer American Joint

Recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +4 more
  • Necitumumab
  • +4 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Jan 5, 2023

Breast Cancer, HER2-positive Breast Cancer Trial in Zhengzhou (Albumin paclitaxel+trastuzumab+pyrrolitinib,

Active, not recruiting
  • Breast Cancer
  • HER2-positive Breast Cancer
  • Zhengzhou, Henan, China
    Henan cancer hospital
Jun 23, 2023

HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma Trial (Trastuzumab deruxtecan)

Not yet recruiting
  • HER2-positive Advanced Gastric Cancer
  • HER2-positive Gastroesophageal Junction Adenocarcinoma
  • Trastuzumab deruxtecan
  • (no location specified)
Aug 11, 2023

Metastatic Breast Cancer Trial in Rome (HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and

Recruiting
  • Metastatic Breast Cancer
  • HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and objectively assess HER2 status at recruitment
  • Rome, Italy
    Fondazione Policlinico A. Gemelli - IRCCS
Jun 22, 2023

DESTINY Breast Respond HER2-low Europe

Not yet recruiting
  • Unresectable Breast Cancer
  • +2 more
  • Trastuzumab deruxtecan
  • (no location specified)
Jul 6, 2023

Breast Cancer Trial (non invasive auricular vagal stimulation, usual medical treatment, sham stimulation)

Not yet recruiting
  • Breast Cancer
  • non invasive auricular vagal stimulation
  • +2 more
  • (no location specified)
May 17, 2022

NSCLC Trial in Netherlands (Trastuzumab emtansine, Osimertinib)

Terminated
  • Carcinoma, Non-Small-Cell Lung
  • Maastricht, Limburg, Netherlands
  • +4 more
Nov 7, 2022

Breast Cancer, HER2-positive Breast Cancer Trial in Zhengzhou (Docetaxel + Carboplatin + Trastuzumab + Pertuzumab, (Epirubicin +

Recruiting
  • Breast Cancer
  • HER2-positive Breast Cancer
  • Docetaxel + Carboplatin + Trastuzumab + Pertuzumab
  • (Epirubicin + Cyclophosphamide - Docetaxel) + (Trastuzumab + Pertuzumab)
  • Zhengzhou, Henan, China
    Henan cancer hospital
Jul 24, 2022

Lymphoma, Non-Hodgkin, Lymphoma, Hodgkin Trial (intervention)

Not yet recruiting
  • Lymphoma, Non-Hodgkin
  • Lymphoma, Hodgkin
  • intervention
  • (no location specified)
Feb 9, 2022

PROVIDENCE - Real-world Study in HER2-positive Unresectable or

Not yet recruiting
  • Breast Neoplasms
  • +2 more
    • (no location specified)
    Oct 7, 2022

    Breast Cancer, Adjuvant Therapy Trial in Fuzhou (Pyrotinib+Trastuzumab+Capecitabine, Trastuzumab+Pertuzumab/Trastuzumab)

    Recruiting
    • Breast Cancer
    • Adjuvant Therapy
    • Fuzhou, Fujian, China
      Fujian Medical University Union Hospital
    Mar 14, 2022

    Breast Cancer Trial in Worldwide (Liposomal doxorubicin HCl, Cyclophosphamide, Trastuzumab)

    Completed
    • Breast Cancer
    • Liposomal doxorubicin hydrochloride
    • +4 more
    • Kufstein, Austria
    • +21 more
    Jun 21, 2022

    HER2 Mutant NSCLC, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation Trial (ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki,

    Not yet recruiting
    • HER2 Mutant Non-small Cell Lung Cancer
    • +3 more
    • (no location specified)
    Dec 6, 2022

    HER2-positive Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer Trial in Belgium, France (Pertuzumab and

    Recruiting
    • HER2-positive Breast Cancer
    • +3 more
    • Pertuzumab and tratuzumab fixed dose combination
    • Trastuzumab emtansine
    • Auchenflower, Australia
    • +84 more
    Jan 16, 2023

    Breast Cancer Trial in Paris, Barcelone, Madrid (Trastuzumab and non-pegylated liposomal doxorubicin)

    Completed
    Has Results
    • Breast Cancer
    • Trastuzumab and non-pegylated liposomal doxorubicin
    • Paris, France
    • +3 more
    Feb 8, 2022

    HER2-positive Metastatic Breast Cancer, Locally Advanced HER2 Positive Breast Carcinoma Trial in Spain (Tucatinib, Trastuzumab,

    Not yet recruiting
    • HER2-positive Metastatic Breast Cancer
    • Locally Advanced HER2 Positive Breast Carcinoma
    • Cádiz, Andalucía, Spain
    • +17 more
    Jan 16, 2023

    Breast Cancer, HER2-positive Breast Cancer Trial in Australia (Tucatinib, Pembrolizumab, Trastuzumab)

    Not yet recruiting
    • Breast Cancer
    • HER2-positive Breast Cancer
    • Albury, New South Wales, Australia
    • +11 more
    May 22, 2022

    Breast Cancer, Triple Negative Breast Cancer Trial in Los Angeles (Durvalumab, Radiation Therapy, Carboplatin)

    Withdrawn
    • Breast Cancer
    • Triple Negative Breast Cancer
    • Los Angeles, California
      Cedars Sinai Medical Center
    Aug 19, 2021

    Metastatic HER2 Positive Gastroesophageal Junction Cancer Trial in La Jolla, Washington, Hackensack (CYNK-101, Pembrolizumab,

    Recruiting
    • Metastatic HER2 Positive Gastroesophageal Junction Cancer
    • CYNK-101
    • +6 more
    • La Jolla, California
    • +2 more
    Jul 12, 2022

    pCR After Neoadjuvant Therapy in Breast Cancer Patients

    Recruiting
    • Breast Cancer
    • TIL assessment in pre-existing histopathological specimens
    • Cairo, Egypt
      Faculty of Medicine, Ain Shams University
    Jul 25, 2022

    Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Stage III, HER2 Gene Mutation Trial in France (pertuzumab +

    Active, not recruiting
    • Non Small Cell Lung Cancer Metastatic
    • +2 more
    • pertuzumab + trastuzumab + docetaxel
    • Besançon, France
    • +17 more
    Mar 9, 2022

    Breast Cancer, Non Hodgkin Lymphoma Trial in Middlesbrough (Enalapril)

    Recruiting
    • Breast Cancer
    • Non Hodgkin Lymphoma
    • Middlesbrough, Teesside, United Kingdom
      South Tees Hospitals NHS FT
    Oct 20, 2022